Ultragenyx Pharmaceutical (RARE) Earnings Date and Reports 2024

Q: Is Ultragenyx a rare disease company?

Ultragenyx is a rare disease company that employs a number of technologies including biologics, small molecules, gene therapy, and nucleic acid. The company's flagship product, Crysvita, was first approved back in 2018 for X-linked hypophosphatemia (XLH) and tacked on another approval for tumor-induced osteomalacia (TIO) in 2020.

Q: How much will Syndax pharmaceuticals earn in 2024?

Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($2.98) to ($3.10) per share. Syndax Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

4 days ago · Ultragenyx Pharmaceutical announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.40, which topped the consensus estimate of -$1.45 by $0.05. …

CouponFollow Extension

$1.40
OFF

Ultragenyx Pharmaceutical (RARE) Earnings Date And Reports 2024

1 week from now

4 days ago · Ultragenyx Pharmaceutical announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.40, which topped the consensus estimate of -$1.45 by $0.05. …

marketbeat.com

3%
OFF

RARE Earnings Dates, Upcoming And Historical Ultragenyx …

1 week from now

The company held a conference call for investors at 5:00 PM eastern on the same day. RARE shares gained +14.3% the day following the earnings announcement to close at 50.47. …

marketchameleon.com

32%
OFF

What Date Does Ultragenyx Pharmaceutical's (RARE) Report …

1 week from now

Oct 22, 2024 · This reflects a positive earnings surprise of 7.32%. Look out for RARE's next earnings release expected on November 07, 2024. For the next earning release, we expect …

zacks.com

22%
OFF

Ultragenyx Pharmaceutical Earnings Dates, Reports, Calls 2014 …

1 week from now

On RARE's earnings call on Invalid Date, . Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 2024 earnings per share (EPS) of -$1.40, up 37.22% year over year. Total RARE …

wallstreetzen.com

$1.40
OFF

Ultragenyx Pharmaceutical Inc. (RARE) Stock Earnings Dates

1 week from now

3 days ago · Ultragenyx Pharmaceutical GAAP EPS of -$1.40 beats by $0.08, revenue of $139.45M beats by $4.2M. SA NewsYesterday, 4:12 PM. Here are the major earnings after …

seekingalpha.com

89%
OFF

Ultragenyx Pharmaceutical (RARE) Earnings Report Date & History

1 week from now

Check Ultragenyx Pharmaceutical's next earnings date, actual and estimated EPS, report history, earnings-related price changes, and more. Total Market Cap: M. Cap: $ 2.26T (3.89%) BTC …

coincodex.com

42%
OFF

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call …

1 week from now

Nov 6, 2024 · Positive Points. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) reported a 42% year-over-year revenue growth for the third quarter of 2024, reaching $139 million. The …

yahoo.com

1%
OFF

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats ...

1 week from now

Ultragenyx Pharmaceutical Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by …

simplywall.st

$116.00
OFF

FY2024 EPS Estimates For RARE Lifted By Cantor Fitzgerald

1 week from now

4 days ago · Cantor Fitzgerald has a “Overweight” rating and a $116.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is …

americanbankingnews.com

68%
OFF

Ultragenyx Pharmaceutical Inc (RARE) - Fidelity International

1 week from now

2 days ago · Buy. $45.47. Change. $-2.23 (-4.68%) Prices updated at 15 Nov 2024, 16:04 BST. Prices minimum 15 mins delay. Prices in USD. Ultragenyx Pharmaceutical Inc is …

fidelity.co.uk

42%
OFF

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats …

1 week from now

Nov 7, 2024 · Ultragenyx Pharmaceutical (NASDAQ:RARE) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$139.5m (up 42% from 3Q 2023). Net loss: US$133.5m (loss …

yahoo.com

$1.41
OFF

Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed

1 week from now

5 days ago · Get Our Latest Research Report on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Stock Down 2.8 %. Shares of NASDAQ RARE traded down $1.41 during …

marketbeat.com

27%
OFF

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

1 week from now

4 days ago · As a result, Ultragenyx maintained their 2024 revenue guidance of $530M-$550M, which would be 225-27% growth year-over-year. Despite their strong top-line marks, …

seekingalpha.com

$0.00
OFF

ARS Pharmaceuticals (SPRY) Earnings Date And Reports 2024

1 week from now

ARS Pharmaceuticals announced Q3 2024 earnings on November 13, 2024, reporting an EPS of $0.00, which beat analysts' consensus estimates of -$0.18 by $0.18. With a trailing EPS of …

marketbeat.com

$0.98
OFF

Syndax Pharmaceuticals (SNDX) Earnings Date And Reports 2024

1 week from now

2 days ago · Syndax Pharmaceuticals posted Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.98, which beat analysts' consensus estimates of -$1.13 by $0.15. Quarterly …

marketbeat.com

$0.20
OFF

Fennec Pharmaceuticals (FENC) Earnings Date And Reports 2024

1 week from now

2 days ago · Fennec Pharmaceuticals released Q2 2024 earnings on August 13, 2024, reporting an EPS of -$0.20, which missed the consensus estimate of $0.06 by $0.26. Quarterly revenue …

marketbeat.com

$4.92
OFF

Madrigal Pharmaceuticals (MDGL) Earnings Date And Reports 2024 …

1 week from now

Madrigal Pharmaceuticals released Q3 2024 earnings on October 31, 2024, reporting an EPS of -$4.92, which beat the consensus estimate of -$6.94 by $2.02. Quarterly revenue was reported …

marketbeat.com

FAQs about Ultragenyx Pharmaceutical (RARE) Earnings Date and Reports 2024 Coupon?

How did Ultragenyx perform in third quarter 2024?

Third Quarter 2024 Selected Financial Data Tables and Financial Results Total Revenues Ultragenyx reported $139 million in total revenue for the third quarter of 2024, which represents 42% growth compared to the same period in 2023. Third quarter 2024 Crysvita revenue was $98 million, which represents 31% growth compared to the same period in 2023. ...

Should I buy Ultragenyx?

Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company’s promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. ...

Is Ultragenyx a good stock to buy by 2026?

The company’s promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. Ultragenyx's $825M cash position and path to profitability by 2026 suggest financial stability, potentially avoiding the need for extensive dilutive financing. ...

Who is Ultragenyx Pharmaceutical?

The Company’s partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 pediatric study in young adults (5 to 25 years old) for setrusumab in OI and in the Phase 3 study in pediatric patients (2 to <7 years old) in the first half of 2024. ...

Is Ultragenyx a rare disease company?

Ultragenyx is a rare disease company that employs a number of technologies including biologics, small molecules, gene therapy, and nucleic acid. The company's flagship product, Crysvita, was first approved back in 2018 for X-linked hypophosphatemia (XLH) and tacked on another approval for tumor-induced osteomalacia (TIO) in 2020. ...

How much will Syndax pharmaceuticals earn in 2024?

Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($2.98) to ($3.10) per share. Syndax Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates. ...